These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 7461567

  • 1. [Prevention of urinary calculi by means of a benzbromarone-citrate combination].
    Bach D, Hesse A, Strenge A, Vahlensieck W.
    Fortschr Med; 1980 Nov 27; 98(44):1752-5. PubMed ID: 7461567
    [Abstract] [Full Text] [Related]

  • 2. [Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].
    Mertz DP.
    Med Klin; 1977 Apr 15; 72(15):664-8. PubMed ID: 857138
    [Abstract] [Full Text] [Related]

  • 3. [Uric acid lowering effects of benzbromarone (Harolan) by increasing uric acid excretion].
    Fortschr Med; 1979 May 03; 97(17):835-6. PubMed ID: 437646
    [No Abstract] [Full Text] [Related]

  • 4. [Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study].
    Arntz HR, Dreykluft HR, Leonhardt H.
    Fortschr Med; 1979 Jul 19; 97(27):1212-4. PubMed ID: 457017
    [Abstract] [Full Text] [Related]

  • 5. The influence of dietary factors on the risk of urinary stone formation.
    Hesse A, Siener R, Heynck H, Jahnen A.
    Scanning Microsc; 1993 Sep 19; 7(3):1119-27; discussion 1127-8. PubMed ID: 8146611
    [Abstract] [Full Text] [Related]

  • 6. [Serum uric acid and uric acid elimination after benzbromarone therapy in patients with gout and hyperuricemia].
    Matzkies F, Neuwirth R, Berg G.
    Fortschr Med; 1976 Sep 16; 94(26):1427-9. PubMed ID: 976920
    [Abstract] [Full Text] [Related]

  • 7. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
    Zerwekh JE, Odvina CV, Wuermser LA, Pak CY.
    J Urol; 2007 Jun 16; 177(6):2179-84. PubMed ID: 17509313
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies (author's transl)].
    Mertz DP.
    MMW Munch Med Wochenschr; 1978 Oct 20; 120(42):1387-90. PubMed ID: 101792
    [Abstract] [Full Text] [Related]

  • 10. Stone forming risk of calcium citrate supplementation in healthy postmenopausal women.
    Sakhaee K, Poindexter JR, Griffith CS, Pak CY.
    J Urol; 2004 Sep 20; 172(3):958-61. PubMed ID: 15311008
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
    Matzkies F, Berg G.
    Dtsch Med Wochenschr; 1976 Oct 22; 101(43):1568-70. PubMed ID: 991731
    [Abstract] [Full Text] [Related]

  • 12. Role of the diurnal variation of urinary pH and urinary calcium in urolithiasis: a study in outpatients.
    Murayama T, Sakai N, Yamada T, Takano T.
    Int J Urol; 2001 Oct 22; 8(10):525-31; discussion 532. PubMed ID: 11737477
    [Abstract] [Full Text] [Related]

  • 13. [The effect of benzbromaron in gout patients with limited kidney function].
    Kuzmits R, Bresnik W, Müller MM.
    Fortschr Med; 1979 Nov 22; 97(44):2057-61. PubMed ID: 511087
    [Abstract] [Full Text] [Related]

  • 14. [Effects and side effects of benzbromaron in the initial treatment of hyperuricemia and gout. Results of a field study on 3899 patients].
    Matzkies F.
    Fortschr Med; 1978 Aug 24; 96(32):1619-21. PubMed ID: 680625
    [Abstract] [Full Text] [Related]

  • 15. [Efficacy and tolerance of a new benzbromarone preparation].
    Jelke K, Neubauer M, Krause G, Jüttner A, Angar T, Grosse-Kielisch C, Bach GL.
    Med Welt; 1980 May 23; 31(21):821-2. PubMed ID: 7392938
    [No Abstract] [Full Text] [Related]

  • 16. Citric acid or citrates in urine: which should we focus on in the prevention of calcium oxalate crystals and stones?
    Laube N, Jansen B, Hesse A.
    Urol Res; 2002 Oct 23; 30(5):336-41. PubMed ID: 12389124
    [Abstract] [Full Text] [Related]

  • 17. [Circadian rhythms of lithogenic and inhibitory substances in the urine].
    Ebisuno S, Morimoto S, Yasukawa S, Yoshida T, Fukatani T, Minakata S, Uehara M, Ohkawa T.
    Hinyokika Kiyo; 1986 May 23; 32(5):667-71. PubMed ID: 3751794
    [Abstract] [Full Text] [Related]

  • 18. [Normurat (benzbromaron) in the treatment of gout].
    Bosmanský K, Trnavský K.
    Z Rheumatol; 1979 May 23; 38(9-10):342-8. PubMed ID: 525067
    [Abstract] [Full Text] [Related]

  • 19. Insulin resistance and low urinary citrate excretion in calcium stone formers.
    Cupisti A, Meola M, D'Alessandro C, Bernabini G, Pasquali E, Carpi A, Barsotti G.
    Biomed Pharmacother; 2007 Jan 23; 61(1):86-90. PubMed ID: 17184967
    [Abstract] [Full Text] [Related]

  • 20. [Treatment of hyperuricemia using daily doses of 50 and 25mg of benzbromarone].
    Matzkies F, Berg G, Minzlaff R.
    Fortschr Med; 1977 Jul 21; 95(27):1748-50. PubMed ID: 332605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.